Literature DB >> 21922182

Resistant hypertension: concepts and approach to management.

Gary E Sander1, Thomas D Giles.   

Abstract

Resistant hypertension (RH), defined simply, is blood pressure (BP) requiring the use of four or more antihypertensive agents, whether controlled or uncontrolled. RH is an increasingly common problem in elderly patients and may affect as many as 20% of the hypertensive population. Unfortunately, at least 30% of patients evaluated for RH are actually adequately controlled when more carefully assessed by home BP monitoring or ambulatory BP monitoring, thus representing a white coat effect. It is also essential to exclude pseudoresistance resulting from improper BP recording techniques or failure of the patient to adhere to the prescribed treatment regimen. Concurrent use of drugs that may interfere with prescribed antihypertensive agents, including many over the counter herbal preparations, must also be excluded. The underlying mechanisms principally driving true RH include pathophysiologic abnormalities of aldosterone signaling, sodium and water retention, excessive sympathetic nervous system activity, and obstructive sleep apnea. Appropriate treatment regimens will usually include an inhibitor of the renin-angiotensin-aldosterone system, a calcium channel blocker, and a diuretic. An aldosterone receptor blocker can be instituted at any step, and is very effective as a fourth drug. Beta-blockers can also be integrated into these treatment plans and may be especially helpful when excessive sympathetic nervous system activity is suspected. Novel device therapies that interrupt sympathetic nerve stimulation at the carotid sinus and kidney are under investigation, and may add entirely new directions in the management of RH. What is most important is that treatment regimens should be targeted to specific patient profiles.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21922182     DOI: 10.1007/s11906-011-0226-7

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  55 in total

1.  Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio.

Authors:  B J Gallay; S Ahmad; L Xu; B Toivola; R C Davidson
Journal:  Am J Kidney Dis       Date:  2001-04       Impact factor: 8.860

2.  Hyperaldosteronism among black and white subjects with resistant hypertension.

Authors:  David A Calhoun; Mari K Nishizaka; Mohammad A Zaman; Roopal B Thakkar; Paula Weissmann
Journal:  Hypertension       Date:  2002-12       Impact factor: 10.190

Review 3.  The kidney, hypertension, and remaining challenges.

Authors:  Nitin Khosla; Rigas Kalaitzidis; George L Bakris
Journal:  Med Clin North Am       Date:  2009-05       Impact factor: 5.456

4.  Dihydropyridine calcium antagonists are associated with increased albuminuria in treatment-resistant hypertensives.

Authors:  Diana Hummel; Ulrike Raff; Thomas K Schwarz; Markus P Schneider; Roland E Schmieder; Bernhard M W Schmidt
Journal:  J Nephrol       Date:  2010 Sep-Oct       Impact factor: 3.902

5.  High prevalence of unrecognized sleep apnoea in drug-resistant hypertension.

Authors:  A G Logan; S M Perlikowski; A Mente; A Tisler; R Tkacova; M Niroumand; R S Leung; T D Bradley
Journal:  J Hypertens       Date:  2001-12       Impact factor: 4.844

6.  Gene variation in resistant hypertension: multilocus analysis of the angiotensin 1-converting enzyme, angiotensinogen, and endothelial nitric oxide synthase genes.

Authors:  Juan Carlos Yugar-Toledo; José Fernando Vilela Martin; José Eduardo Krieger; Alexandre C Pereira; Caroline Demacq; Otávio Rizzi Coelho; Eduardo Pimenta; David A Calhoun; Heitor Moreno Júnior
Journal:  DNA Cell Biol       Date:  2011-03-27       Impact factor: 3.311

7.  Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease.

Authors:  Paolo Verdecchia; Peter Sleight; Giuseppe Mancia; Robert Fagard; Bruno Trimarco; Roland E Schmieder; Jae-Hyung Kim; Garry Jennings; Petr Jansky; Jyh-Hong Chen; Lisheng Liu; Peggy Gao; Jeffrey Probstfield; Koon Teo; Salim Yusuf
Journal:  Circulation       Date:  2009-09-21       Impact factor: 29.690

8.  Tubular hypertrophy due to work load induced by furosemide is associated with increases of IGF-1 and IGFBP-1.

Authors:  S Kobayashi; D R Clemmons; H Nogami; A K Roy; M A Venkatachalam
Journal:  Kidney Int       Date:  1995-03       Impact factor: 10.612

9.  Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research.

Authors:  David A Calhoun; Daniel Jones; Stephen Textor; David C Goff; Timothy P Murphy; Robert D Toto; Anthony White; William C Cushman; William White; Domenic Sica; Keith Ferdinand; Thomas D Giles; Bonita Falkner; Robert M Carey
Journal:  Hypertension       Date:  2008-04-07       Impact factor: 10.190

10.  Influence of time of day of blood pressure-lowering treatment on cardiovascular risk in hypertensive patients with type 2 diabetes.

Authors:  Ramón C Hermida; Diana E Ayala; Artemio Mojón; José R Fernández
Journal:  Diabetes Care       Date:  2011-06       Impact factor: 19.112

View more
  6 in total

Review 1.  Device-Based Therapy for Drug-Resistant Hypertension: An Update.

Authors:  Ping Li; Mark Nader; Kousalya Arunagiri; Vasilios Papademetriou
Journal:  Curr Hypertens Rep       Date:  2016-08       Impact factor: 5.369

Review 2.  Resistant or refractory hypertension: are they different?

Authors:  Rodrigo Modolo; Ana Paula de Faria; Aurélio Almeida; Heitor Moreno
Journal:  Curr Hypertens Rep       Date:  2014-10       Impact factor: 5.369

Review 3.  Is it possible to manage hypertension and evaluate therapy without ambulatory blood pressure monitoring?

Authors:  William B White; Spyridoula Maraka
Journal:  Curr Hypertens Rep       Date:  2012-08       Impact factor: 5.369

Review 4.  Managing hypertension with ambulatory blood pressure monitoring.

Authors:  William B White; Vinay Gulati
Journal:  Curr Cardiol Rep       Date:  2015-02       Impact factor: 2.931

Review 5.  Effect of aldosterone antagonists on blood pressure in patients with resistant hypertension: a meta-analysis.

Authors:  G Liu; X X Zheng; Y L Xu; J Lu; R T Hui; X H Huang
Journal:  J Hum Hypertens       Date:  2014-07-31       Impact factor: 3.012

6.  A prospective randomized trial examining health care utilization in individuals using multiple smartphone-enabled biosensors.

Authors:  Cinnamon S Bloss; Nathan E Wineinger; Melissa Peters; Debra L Boeldt; Lauren Ariniello; Ju Young Kim; Judith Sheard; Ravi Komatireddy; Paddy Barrett; Eric J Topol
Journal:  PeerJ       Date:  2016-01-14       Impact factor: 2.984

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.